– Detailed Results from the Phase 1/2a Study of ARO-DIMER-PA, the First Dual-Functional Investigational RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia, Will Be Presented at Late-breaking Featured Science Session.05 on Saturday, November 7 –

– Pooled SHASTA-3/4 Analysis of Triglyceride Lowering and Acute Pancreatitis (AP) Risk Reduction with Plozasiran in Severe Hypertriglyceridemia (sHTG) Also To Be Presented at Late-Breaking Featured Science Session.05 –

–Long Term Efficacy and Safety of Plozasiran in Patients with Familial Chylomicronemia Syndrome: Three-Year Data from the PALISADE Study and the Open-Label Extension Will Be Presented in Moderated Poster Session –

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced today that it will present important data at this week’s American Heart Association Scientific Sessions in Chicago.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.